Stock Ratings | Raymond James raised its target price for Micron (MU) to $1,100; Ascendiant raised its target price for RenovoRx (RNXT) to $14, indicating a potential upside of 1,420.58%
RenovoRx, Inc. RNXT | 0.00 | |
Jade Biosciences, Inc. JBIO | 0.00 | |
REalloys Inc. ALOY | 0.00 | |
GRI Bio GRI | 0.00 | |
Advanced Micro Devices, Inc. AMD | 0.00 |
The ratings of major US investment banks are used to track the latest valuations and target prices on Wall Street daily, and to explore potential equity investment opportunities.
Risk warning:
Investing in small-cap stocks can be risky. Be prepared for potential challenges related to liquidity, high volatility, limited information, and financial instability. Always diversify your investments.
Today's key assessments and concerns
Ascendiant Capital: Maintains its "Buy" rating on RenovoRx RenovoRx(RNXT.US) ), raising its price target from $13.5 to $14.
BTIG: Maintaining a "buy" rating on Jade Biosciences ( Jade Biosciences(JBIO.US) ), while raising the price target from $39 to $74.
HC Wainwright & Co.: Maintaining a "buy" rating on Jade Biosciences ( Jade Biosciences(JBIO.US) ), with a price target raised from $45 to $55.
Needham: Initial rating for REalloys ( REalloys Inc.(ALOY.US) ) stock at "buy", with a target price of $19.
Ascendiant Capital: Maintaining its "Buy" rating on GRI Bio ( GRI Bio(GRI.US) ), while lowering its price target from $40 to $32.
| The symbol | Classification | Target price | Current price | Percentage of potential increase/decrease | (Classification) Agency |
| RNXT | to lift | $14.0 | $0.9207 | 1420.58% | Ascendiant Capital |
| JBIO | to lift | $74.0 | $18.59 | 298.06% | BTIG |
| JBIO | to lift | $55.0 | $18.59 | 195.86% | HC Wainwright & Co. |
| CCCC | to lift | $12.0 | $4.38 | 173.97% | Evercore ISI Group |
| AAL | to lift | $24.0 | $14.34 | 67.36% | Morgan Stanley |
| ALOY | Initial classification | $19.0 | $10.99 | 72.88% | Needham |
| GRI | cut | $32.0 | $2.07 | 1445.89% | Ascendiant Capital |
| AIM | cut | $9.0 | $0.8986 | 901.56% | Ascendiant Capital |
| RNTX | cut | $8.0 | $1.07 | 647.66% | HC Wainwright & Co. |
| NDRA | cut | $25.0 | $5.6 | 346.43% | Ascendiant Capital |
Target price unit and current price: US Dollar;
Current price: As of the latest closing price of US stocks;
Potential percentage increase/potential decrease = (Agency target price - current price) / current price 100% (Current price = Last closing price up to the time of the count)
Lifting
Mizuho: Maintaining Advanced Micro Devices, Inc.(AMD.US) rating at "Outperform Market", while raising the price target from $515 to $615.
Raymond James: Maintaining an "outperform" rating for Micron Technology Micron Technology, Inc.(MU.US) ), while raising the price target from $530 to $1100.
Mizuho: Maintaining its rating on Arm Holdings ( Arm Holdings(ARM.US) ) at "Outperforming the Market," while raising its price target from $360 to $425.
Wells Fargo: Maintaining Arm Holdings(ARM.US) Holdings' rating at "overweight", while raising the price target from $255 to $410.
Mizuho: Maintaining its "Outperform Market" rating for Credo Technology Group Credo Technology(CRDO.US) ), while raising its price target from $220 to $260.
Bernstein: Maintaining Dell's ( Dell Technologies, Inc. Class C(DELL.US) ) rating at "Outperforming the Market," while raising the price target from $280 to $500.
Goldman Sachs: Maintaining a "buy" rating on Dell Dell Technologies, Inc. Class C(DELL.US) stock, while raising its price target from $230 to $500.
Morgan Stanley: Upgraded Dell Dell Technologies, Inc. Class C(DELL.US) ) stock to "market-weighted", raising its price target from $170 to $448.
Piper Sandler: Maintaining Alphabet's ( Alphabet Inc. Class A(GOOGL.US) ) rating at "overweight", while raising the price target from $425 to $445.
Barclays: Maintaining Intel's Intel Corporation(INTC.US) rating at "market-weighted", while raising the price target from $65 to $100.
Mizuho: Maintaining Intel's Intel Corporation(INTC.US) ) rating at "neutral", while raising the price target from $124 to $128.
Wells Fargo: Maintaining Microsoft's ( Microsoft Corporation(MSFT.US) ) rating at "overweight", while raising the target price from $625 to $650.
JP Morgan: Maintaining Palo Alto Networks’ Palo Alto Networks, Inc.(PANW.US) ) rating at “overweight”, while raising the price target from $200 to $300.
Mizuho: Maintaining a "neutral" rating on Super Micro Computer ( Super Micro Computer, Inc.(SMCI.US) ), while raising the price target from $36 to $44.
First Coverage
JP Morgan: Initial rating for Apple Hospitality REIT ( Apple Hospitality REIT Inc(APLE.US) ) at "neutral", with a price target of $15.
Barclays: Initial rating for IBM IBM Corp(IBM.US) ) stock at "overweight", with a price target of $350.
Citizens: Initial rating for Microsoft ( Microsoft Corporation(MSFT.US) ) stock at "outperform," with a price target of $550.
Needham: Initial rating for USA Rare Earth ( USA Rare Earth(USAR.US) ) stock at "Buy", with a target price of $39.
reduction
Mizuho: Maintaining Strategy ( Strategy(MSTR.US) ) rating at "Outperform Market", while lowering the price target from $320 to $265.
Jefferies: Downgraded Redwire Corp ( Redwire(RDW.US) ) stock to "Hold," while raising its price target from $13 to $24.
Wells Fargo: Maintaining STAG Industrial STAG Industrial, Inc.(STAG.US) ) rating at "Market-Similar Weight", while lowering the price target from $41 to $40.
Wells Fargo: Maintaining a "Market-Similar Weight" rating for Tremont Realty Trust ( Terreno Realty Corporation(TRNO.US) ), while lowering its price target from $68 to $64.
Editor's Note: This content was created by Saham's AI-powered SaaS tool and reviewed by our editorial team.
Risk Warning: Investing involves risk. Securities may rise, fall, or become worthless. Investing does not guarantee profits and may result in losses. Past performance is not necessarily indicative of future results. Before making any investment decision, investors should assess their financial situation, investment objectives, experience, risk tolerance, and understand the nature of the investment products and their associated risks. For more details on the nature and risks of each investment product, please read the relevant offering documents carefully. If you have any questions, it is advisable to seek independent professional advice.
